S K Klein
Overview
Explore the profile of S K Klein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kockerols C, Valk P, Hogenbirk P, Geelen I, Blijlevens N, Janssen J, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39957332
Approximately 40%-60% of patients reaching a stable deep molecular response during TKI treatment will maintain a state of remission after TKI discontinuation, denoted as treatment-free remission (TFR). Depth of molecular...
2.
Seefat M, Stege C, Lissenberg-Witte B, Levin M, Timmers G, Hoogendoorn M, et al.
Eur J Cancer
. 2024 Jun;
207:114153.
PMID: 38870747
Background: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and...
3.
van de Loosdrecht A, Cremers E, Alhan C, Duetz C, In t Hout F, Visser-Wisselaar H, et al.
Leukemia
. 2024 Jan;
38(4):840-850.
PMID: 38297135
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients...
4.
Janssen J, Lowenberg B, Manz M, Biemond B, Westerweel P, Klein S, et al.
Leukemia
. 2022 Jul;
36(9):2189-2195.
PMID: 35869267
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would...
5.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Aug;
34(10):2820.
PMID: 32733013
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Cruijsen M, van der Velden W, de Haan A, Klein S, Hoogendoorn M, Tromp Y, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2752-2755.
PMID: 32530341
No abstract available.
7.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Feb;
34(7):1751-1759.
PMID: 32020044
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome....
8.
Nijhof I, Groen R, Lokhorst H, van Kessel B, Bloem A, van Velzen J, et al.
Leukemia
. 2015 May;
29(10):2039-49.
PMID: 25975191
Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity). Owing to a marked heterogeneity of response...
9.
Vos J, Minnema M, Wijermans P, Croockewit S, Chamuleau M, Pals S, et al.
Neth J Med
. 2013 Mar;
71(2):54-62.
PMID: 23462052
On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of...
10.
Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J, et al.
Leukemia
. 2011 Jul;
26(1):149-57.
PMID: 21799510
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural...